Drug Trial Radar · NCT07927218
Study of Food Effects of VV261 Tablets in Healthy Trial Participants
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
Dec 30, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, open-label, three-cycle, self-cross-over study on human pharmacokinetic characteristics under fasting, standard meal, and high-fat meal conditions.
Conditions
- Severe Fever With Thrombocytopenia Syndrome
Interventions
VV261Drug
A group:600 mg VV261, following an overnight fast of at least 10 hours for Period 1 ;600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 2 ; 600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 3;
VV261Drug
B group:600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 1 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 2 ; 600 mg VV261, administered 30 minutes after the start of a Standard meal for Period 3;
VV261Drug
C group:administered 30 minutes after the start of a Standard meal for Period 1;600 mg VV261, administered 30 minutes after the start of the high-fat meal for Period 2 ; 600 mg VV261, following an overnight fast of at least 10 hours for Period 3 ;
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Baseline to 96 hours after the last administration
- TmaxTime frame: Baseline to 96 hours after the last administration
- AUC0-tTime frame: Baseline to 96 hours after the last administration
- AUC0-∞Time frame: Baseline to 96 hours after the last administration
- t1/2Time frame: Baseline to 96 hours after the last administration
- CL/FTime frame: Baseline to 96 hours after the last administration
- mean Resident TimeTime frame: Baseline to 96 hours after the last administration
- Vd/FTime frame: Baseline to 96 hours after the last administration
- Incidence of Treatment-Emergent Adverse EventsTime frame: Baseline to 7days after the last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.